2 results about "Systolic function" patented technology

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.

The application discloses application of raloxifene or a pharmaceutical salt thereof in preparation of a medicine for treating sepsis cardiomyopathy, and simultaneously discloses application of a STAT3 protein Tyr705 site as a sepsis cardiomyopathy treatment target, and belongs to the technical field of biological medicines. The application proves through in-vivo and in-vitro experiments that raloxifene can effectively improve body temperature drop and left ventricular systolic function reduction related to sepsis cardiomyopathy, reduce myocardial inflammatory infiltration, relieve myocardial oxidative stress, mitochondrial dysfunction and energy metabolism disorder, and play a definite myocardial protection role by inhibiting phosphorylation activation of the STAT3 protein Tyr705 site in myocardial tissue and cells. The application provides a novel targeted treatment strategy and drug selection for sepsis cardiomyopathy, and has a good clinical transformation application prospect.